脉络膜上腔注射CLS-TA治疗非感染性葡萄膜炎的安全性研究
AZALEA研究是一项开放标签、前瞻性多中心安全性研究,纳入38例非感染性葡萄膜炎(伴或不伴黄斑水肿)受试者,每12周接受一次脉络膜上腔注射CLS-TA 4 mg,共两次,随访24周。结果显示CLS-TA安全且耐受良好,血浆TA浓度<1 ng/mL,疗效参数在24周内改善。
要点
- 38例非感染性葡萄膜炎受试者接受两次脉络膜上腔CLS-TA 4 mg注射,间隔12周。
- 6例(15.8%)研究眼眼压较基线升高>10 mm Hg,2例(5.3%)眼压>30 mm Hg。
- 注射后血浆TA浓度可量化值<1 ng/mL,疗效参数24周内改善。
核心结论
- 脉络膜上腔注射CLS-TA在非感染性葡萄膜炎(伴或不伴黄斑水肿)受试者中24周内安全且耐受良好。
研究设计与样本
- 开放标签、前瞻性多中心安全性研究,纳入38例非感染性葡萄膜炎受试者,伴或不伴黄斑水肿。
- 治疗为两次脉络膜上腔注射CLS-TA 4 mg,间隔12周,每4周随访至24周。
主要发现
- 基于中心子区厚度>300 µm,38例中20例基线有黄斑水肿。
- 研究眼平均眼压基线13.3 mm Hg,第24周15.2 mm Hg。
- 6例(15.8%)研究眼眼压较基线升高>10 mm Hg,2例(5.3%)眼压>30 mm Hg(第8周最高34 mm Hg,第20周最高38 mm Hg)。
- 4只研究眼报告白内障形成不良事件,其中1只 deemed 治疗相关。
- 研究眼未发生严重眼部不良事件,注射后血浆TA可量化浓度<1 ng/mL,疗效参数24周内改善。
临床怎么用
- 对于非感染性葡萄膜炎伴或不伴黄斑水肿患者,脉络膜上腔CLS-TA 4 mg间隔12周注射两次在24周内安全可耐受。
- 治疗期间需监测眼压,部分患者可能出现眼压升高>10 mm Hg或>30 mm Hg。
- 需关注白内障形成不良事件,多数未判定为治疗相关。
局限性
- 开放标签、单臂设计,样本量38例,随访24周,无对照组的比较性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate local and systemic safety of suprachoroidal (SC) triamcinolone acetonide injectable suspension (CLS-TA) injections in subjects with non-infectious uveitis (NIU). DESIGN: Open-label, prospective multicentre safety study. PARTICIPANTS: Thirty-eight subjects with NIU, with and without macular oedema (MO). METHODS: Treatment consisted of two suprachoroidal injections of CLS-TA 4 mg, 12 weeks apart. Best-corrected visual acuity (BCVA), adverse event (AE) assessment, ophthalmic examinations and optical coherence tomography (OCT) were conducted every 4 weeks for 24 weeks. Blood samples were analysed for plasma triamcinolone acetonide (TA) concentrations. MAIN OUTCOME MEASURES: The main outcome measure was frequency of AEs. Other endpoints included plasma TA concentrations, change in signs of inflammation, BCVA and retinal central subfield thickness (CST). RESULTS: Based on a CST of >300 µm, 20 out of 38 subjects had MO at baseline. Mean intraocular pressure (IOP) was 13.3 mm Hg at baseline and 15.2 mm Hg at week 24 in the study eye. A total of six (15.8%) subjects had an IOP rise >10 mm Hg compared with baseline, in the study eye, and two (5.3%) subjects had IOP >30 mm Hg (maximum 34 mm Hg at week 8 and 38 mm Hg at week 20). Cataract formation AEs were reported in four study eyes; one of which was deemed treatment-related. No serious ocular AEs in the study eye occurred in the study. Quantifiable post-injection TA plasma concentration was <1 ng/mL. Efficacy parameters showed improvement over the 24-week study period. CONCLUSIONS: Suprachoroidally administered CLS-TA was safe and well tolerated over the 24-week, open-label study in NIU subjects with and without MO.
引用
- Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol. 2021. PMID: 33547034. doi:10.1136/bjophthalmol-2020-318019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。